Broderick Brian C Has $432,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Broderick Brian C reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 67.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,793 shares of the medical instruments supplier’s stock after selling 3,782 shares during the period. Broderick Brian C’s holdings in Becton, Dickinson and Company were worth $432,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in BDX. PineStone Asset Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 141.6% in the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock worth $314,544,000 after acquiring an additional 788,735 shares during the period. M&G Plc bought a new position in Becton, Dickinson and Company in the first quarter valued at $173,692,000. First Eagle Investment Management LLC increased its holdings in shares of Becton, Dickinson and Company by 32.5% in the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after buying an additional 688,296 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Becton, Dickinson and Company by 8.5% during the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after buying an additional 346,720 shares during the period. Finally, Magnetar Financial LLC purchased a new stake in Becton, Dickinson and Company in the first quarter worth $75,493,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Evercore ISI raised their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Raymond James cut their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Finally, Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Trading Down 1.7 %

Becton, Dickinson and Company stock opened at $227.23 on Friday. The company’s fifty day simple moving average is $236.56 and its 200-day simple moving average is $235.10. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89. The stock has a market cap of $65.68 billion, a P/E ratio of 38.25, a P/E/G ratio of 1.72 and a beta of 0.43. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.42 earnings per share. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.83%. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 63.97%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.